In that analysis, colitis was the most common cause of death arising from an irAE in patients receiving anti-CTLA-4 antibodies (135 of 193 deaths (70%)), and the combination of anti-CTLA-4 and anti-PD-1 antibodies increased the incidence and severity of irAEs [82]. This evidence concerns the gene CTLA4 and colitis.